10x Genomics, Inc. (NASDAQ:TXG) Shares Sold by Marshall Wace LLP

Marshall Wace LLP cut its stake in shares of 10x Genomics, Inc. (NASDAQ:TXG - Free Report) by 90.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 46,861 shares of the company's stock after selling 420,262 shares during the quarter. Marshall Wace LLP's holdings in 10x Genomics were worth $673,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in the company. Jump Financial LLC boosted its position in 10x Genomics by 14.0% during the fourth quarter. Jump Financial LLC now owns 185,101 shares of the company's stock worth $2,658,000 after acquiring an additional 22,789 shares during the last quarter. XTX Topco Ltd boosted its stake in shares of 10x Genomics by 17.3% in the fourth quarter. XTX Topco Ltd now owns 52,788 shares of the company's stock valued at $758,000 after purchasing an additional 7,780 shares during the period. Barclays PLC increased its position in shares of 10x Genomics by 31.3% during the fourth quarter. Barclays PLC now owns 790,957 shares of the company's stock worth $11,357,000 after acquiring an additional 188,421 shares during the last quarter. Capital Fund Management S.A. boosted its stake in shares of 10x Genomics by 36.3% during the 4th quarter. Capital Fund Management S.A. now owns 304,832 shares of the company's stock valued at $4,377,000 after buying an additional 81,164 shares during the last quarter. Finally, Raymond James Financial Inc. bought a new position in shares of 10x Genomics during the fourth quarter worth about $431,000. 84.68% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

TXG has been the subject of a number of recent research reports. Stifel Nicolaus lowered their price objective on 10x Genomics from $21.00 to $18.00 and set a "buy" rating for the company in a research note on Thursday, February 13th. JPMorgan Chase & Co. dropped their price target on 10x Genomics from $14.00 to $12.00 and set a "neutral" rating on the stock in a research note on Thursday, February 13th. Citigroup lowered their price target on 10x Genomics from $20.00 to $15.00 and set a "buy" rating on the stock in a report on Tuesday, March 4th. Canaccord Genuity Group lowered their price target on shares of 10x Genomics from $20.00 to $18.00 and set a "buy" rating on the stock in a report on Thursday, February 13th. Finally, UBS Group dropped their price target on shares of 10x Genomics from $20.00 to $14.00 and set a "neutral" rating on the stock in a research note on Thursday, February 13th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $18.85.

Insider Buying and Selling at 10x Genomics

In other news, Director Alan Mateo acquired 40,000 shares of the firm's stock in a transaction on Friday, February 21st. The stock was acquired at an average price of $11.14 per share, for a total transaction of $445,600.00. Following the completion of the transaction, the director now owns 61,691 shares in the company, valued at approximately $687,237.74. The trade was a 184.41 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Serge Saxonov sold 5,092 shares of the stock in a transaction on Monday, February 24th. The shares were sold at an average price of $11.07, for a total value of $56,368.44. Following the completion of the transaction, the chief executive officer now directly owns 879,482 shares of the company's stock, valued at approximately $9,735,865.74. This represents a 0.58 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 10.03% of the company's stock.

10x Genomics Stock Performance

Shares of NASDAQ TXG traded up $0.21 during trading on Wednesday, hitting $8.31. The company had a trading volume of 4,168,810 shares, compared to its average volume of 2,284,713. The stock has a 50 day simple moving average of $9.00 and a 200 day simple moving average of $12.67. The firm has a market capitalization of $1.02 billion, a P/E ratio of -5.47 and a beta of 1.94. 10x Genomics, Inc. has a 12 month low of $6.78 and a 12 month high of $28.25.

10x Genomics (NASDAQ:TXG - Get Free Report) last posted its earnings results on Wednesday, February 12th. The company reported ($0.40) EPS for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.08). 10x Genomics had a negative return on equity of 25.40% and a negative net margin of 29.90%. As a group, analysts predict that 10x Genomics, Inc. will post -1.43 EPS for the current year.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.